

JC474 U.S. PTO  
12/20/00

Please type a plus sign (+) inside this box ☐

Attorney Docket P1729C1

PATENT

CERTIFICATION UNDER 37 CFR 1.10

EM 168886705 US: Express Mail Number December 20, 2000: Date of Deposit

I hereby certify that this Non-provisional Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

*Richard B. Love*  
Richard B. Love

JC474 U.S. PTO  
09/811384  
12/20/00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION  
Assistant Commissioner of Patents  
Washington, D.C. 20231

**NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)**

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

**Martin M. Bednar  
Cordell E. Gross  
G. Roger Thomas**

Title: **Anti-CD18 Antibodies in Stroke**

**1. Type of Application**

- ☐ This application is for an original, non-provisional application.
- ☐ This is a non-provisional application claiming priority to provisional application no. \_\_, filed \_\_, the entire disclosure of which is hereby incorporated by reference.
- ☒ This is a ☐ continuation-in-part ☒ continuation ☐ divisional application claiming priority to application Serial Number 09/251,652, filed 17 February 1999, which is a continuation-in-part application claiming priority to non-provisional application 08/788,800 filed 22 January 1997, which claims priority to provisional application 60/093,038 filed 23 January 1996 (which was converted from non-provisional application U.S. Ser. No. 08/589,982), the entire disclosures of which are hereby incorporated by reference.

**2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b)  
(Non-provisional )**

40 pages of specification  
2 pages of claims  
1 page(s) of abstract

09/811384-12/20/00

1 page(s) of abstract  
5 sheet(s) of drawings  
☐ formal ☒ informal

### 3. Declaration or Oath

*(for new and CIP applications; also for Cont./Div. where inventor(s) are being added)*  
X An unsigned execution declaration of the inventor is enclosed. An executed declaration of the inventors will follow.

*(for Cont./Div. where inventorship is the same or inventor(s) being deleted)*  
— A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).

*(for Cont./Div. where inventor(s) being deleted)*  
— A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).

### 4. Assignment

*(for new and CIP applications)*  
— An Assignment of the invention to GENENTECH, INC. ☐ is enclosed with attached Recordation Form Cover Sheet ☐ will follow.

*(for cont./div.)*  
X The prior application is assigned of record to Genentech, Inc.

### 5. Amendments (for continuation and divisional applications)

— Cancel in this application original claims \_\_\_ of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

X A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

#### Relate Back -- 35 U.S.C. 120 or 35 U.S.C. 119

— Amend the specification by inserting before the first line the sentence:

--This is a

— non-provisional application  
— continuation  
— divisional  
— continuation-in-part

of co-pending application(s)

- \_\_\_\_\_ Serial\_ filed on, which application(s) is(are) incorporated herein by reference and to which application(s) priority is claimed under 35 USC §120. --
- \_\_\_\_\_ International Application \_ filed on \_ which designated the U.S., which application(s) is(are) incorporated herein by reference and to which application(s) priority is claimed under 35 USC §120.--
- \_\_\_\_\_ provisional application No. \_ filed \_\_, the entire disclosure of which is hereby incorporated by reference and to which application(s) priority is claimed under 35 USC §119.--

#### 6. Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

CLAIMS FOR FEE CALCULATION					
Number Filed		Number Extra		Rate	Basic Fee 37 CFR 1.16(a)
					\$710.00
Total Claims	18	- 20 =	0	X \$18.00	\$0.00
Independent Claims	1	- 3 =	0	X \$80.00	\$0.00
Multiple dependent claim(s), if any				+ \$270.00	\$0.00
Filing Fee Calculation					\$710.00

#### 7. Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$710.00 **A duplicate copy of this transmittal is enclosed.**

#### 8. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. **A duplicate copy of this sheet is enclosed.**

#### 9. Additional Papers Enclosed

- ☒ Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations
- ☒ Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence.
- ☐ A new Power of Attorney or authorization of agent.
- ☐ Other: Petition to Extend Time (five months)

#### 10. Maintenance of Copendency of Prior Application (for continuation and divisional applications)

X   A petition, fee and/or response is filed herewith to extend the term  
in the pending prior application until December 20, 2000.

       A copy of the petition for extension of time in the **prior** application  
is attached.

X Address all future communications to:

Respectfully submitted,  
GENENTECH, INC.

By: Richard B. Love  
Richard B. Love  
Reg. No. 34,659  
Telephone No. (650) 225-5530




09157

PATENT TRADEMARK OFFICE

Region	Gene	Accession	Length (bp)	GC (%)	GC (3rd pos) (%)	GC (4th pos) (%)	GC (5th pos) (%)	GC (6th pos) (%)	GC (7th pos) (%)	GC (8th pos) (%)	GC (9th pos) (%)	GC (10th pos) (%)	GC (11th pos) (%)	GC (12th pos) (%)	GC (13th pos) (%)	GC (14th pos) (%)	GC (15th pos) (%)	GC (16th pos) (%)	GC (17th pos) (%)	GC (18th pos) (%)	GC (19th pos) (%)	GC (20th pos) (%)	GC (21st pos) (%)	GC (22nd pos) (%)	GC (23rd pos) (%)	GC (24th pos) (%)	GC (25th pos) (%)	GC (26th pos) (%)	GC (27th pos) (%)	GC (28th pos) (%)	GC (29th pos) (%)	GC (30th pos) (%)	GC (31st pos) (%)	GC (32nd pos) (%)	GC (33rd pos) (%)	GC (34th pos) (%)	GC (35th pos) (%)	GC (36th pos) (%)	GC (37th pos) (%)	GC (38th pos) (%)	GC (39th pos) (%)	GC (40th pos) (%)	GC (41st pos) (%)	GC (42nd pos) (%)	GC (43rd pos) (%)	GC (44th pos) (%)	GC (45th pos) (%)	GC (46th pos) (%)	GC (47th pos) (%)	GC (48th pos) (%)	GC (49th pos) (%)	GC (50th pos) (%)	GC (51st pos) (%)	GC (52nd pos) (%)	GC (53rd pos) (%)	GC (54th pos) (%)	GC (55th pos) (%)	GC (56th pos) (%)	GC (57th pos) (%)	GC (58th pos) (%)	GC (59th pos) (%)	GC (60th pos) (%)	GC (61st pos) (%)	GC (62nd pos) (%)	GC (63rd pos) (%)	GC (64th pos) (%)	GC (65th pos) (%)	GC (66th pos) (%)	GC (67th pos) (%)	GC (68th pos) (%)	GC (69th pos) (%)	GC (70th pos) (%)	GC (71st pos) (%)	GC (72nd pos) (%)	GC (73rd pos) (%)	GC (74th pos) (%)	GC (75th pos) (%)	GC (76th pos) (%)	GC (77th pos) (%)	GC (78th pos) (%)	GC (79th pos) (%)	GC (80th pos) (%)	GC (81st pos) (%)	GC (82nd pos) (%)	GC (83rd pos) (%)	GC (84th pos) (%)	GC (85th pos) (%)	GC (86th pos) (%)	GC (87th pos) (%)	GC (88th pos) (%)	GC (89th pos) (%)	GC (90th pos) (%)	GC (91st pos) (%)	GC (92nd pos) (%)	GC (93rd pos) (%)	GC (94th pos) (%)	GC (95th pos) (%)	GC (96th pos) (%)	GC (97th pos) (%)	GC (98th pos) (%)	GC (99th pos) (%)	GC (100th pos) (%)
Region 1	Gene 1	Accession 1	Length 1 (bp)	GC 1 (%)	GC 3rd pos 1 (%)	GC 4th pos 1 (%)	GC 5th pos 1 (%)	GC 6th pos 1 (%)	GC 7th pos 1 (%)	GC 8th pos 1 (%)	GC 9th pos 1 (%)	GC 10th pos 1 (%)	GC 11th pos 1 (%)	GC 12th pos 1 (%)	GC 13th pos 1 (%)	GC 14th pos 1 (%)	GC 15th pos 1 (%)	GC 16th pos 1 (%)	GC 17th pos 1 (%)	GC 18th pos 1 (%)	GC 19th pos 1 (%)	GC 20th pos 1 (%)	GC 21st pos 1 (%)	GC 22nd pos 1 (%)	GC 23rd pos 1 (%)	GC 24th pos 1 (%)	GC 25th pos 1 (%)	GC 26th pos 1 (%)	GC 27th pos 1 (%)	GC 28th pos 1 (%)	GC 29th pos 1 (%)	GC 30th pos 1 (%)	GC 31st pos 1 (%)	GC 32nd pos 1 (%)	GC 33rd pos 1 (%)	GC 34th pos 1 (%)	GC 35th pos 1 (%)	GC 36th pos 1 (%)	GC 37th pos 1 (%)	GC 38th pos 1 (%)	GC 39th pos 1 (%)	GC 40th pos 1 (%)	GC 41st pos 1 (%)	GC 42nd pos 1 (%)	GC 43rd pos 1 (%)	GC 44th pos 1 (%)	GC 45th pos 1 (%)	GC 46th pos 1 (%)	GC 47th pos 1 (%)	GC 48th pos 1 (%)	GC 49th pos 1 (%)	GC 50th pos 1 (%)	GC 51st pos 1 (%)	GC 52nd pos 1 (%)	GC 53rd pos 1 (%)	GC 54th pos 1 (%)	GC 55th pos 1 (%)	GC 56th pos 1 (%)	GC 57th pos 1 (%)	GC 58th pos 1 (%)	GC 59th pos 1 (%)	GC 60th pos 1 (%)	GC 61st pos 1 (%)	GC 62nd pos 1 (%)	GC 63rd pos 1 (%)	GC 64th pos 1 (%)	GC 65th pos 1 (%)	GC 66th pos 1 (%)	GC 67th pos 1 (%)	GC 68th pos 1 (%)	GC 69th pos 1 (%)	GC 70th pos 1 (%)	GC 71st pos 1 (%)	GC 72nd pos 1 (%)	GC 73rd pos 1 (%)	GC 74th pos 1 (%)	GC 75th pos 1 (%)	GC 76th pos 1 (%)	GC 77th pos 1 (%)	GC 78th pos 1 (%)	GC 79th pos 1 (%)	GC 80th pos 1 (%)	GC 81st pos 1 (%)	GC 82nd pos 1 (%)	GC 83rd pos 1 (%)	GC 84th pos 1 (%)	GC 85th pos 1 (%)	GC 86th pos 1 (%)	GC 87th pos 1 (%)	GC 88th pos 1 (%)	GC 89th pos 1 (%)	GC 90th pos 1 (%)	GC 91st pos 1 (%)	GC 92nd pos 1 (%)	GC 93rd pos 1 (%)	GC 94th pos 1 (%)	GC 95th pos 1 (%)	GC 96th pos 1 (%)	GC 97th pos 1 (%)	GC 98th pos 1 (%)	GC 99th pos 1 (%)	GC 100th pos 1 (%)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<p>In re Rule 53(b) Continuation of Application U.S. Serial No.: 09/251,652  Filed: 17 FEBRUARY 1999  For: CO-ADMINISTRATION OF A THROMBOLYTIC AND AN ANTI- CD18 ANTIBODY</p>	<p>Group Art Unit: Not Yet Assigned  Examiner: Not assigned  EM 168886705 US: Express Mail Number December 20, 2000: Date of Deposit  I hereby certify that this correspondence, consisting of Formal Documents for P1729C1, is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.  December 20, 2000   Richard B. Love</p>
---	---

CERTIFICATE RE: SEQUENCE LISTING


Box Application  
Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

I hereby state that the Sequence Listing submitted herewith is submitted in paper copy and a computer-readable diskette, and that the information recorded in computer readable form is identical to the written sequence listing.

Respectfully submitted,  
GENENTECH, INC.

Date: December 20, 2000

By:   
Richard B. Love  
Reg. No. 34,659  
Telephone No. (650) 225-5530



09157

PATENT TRADEMARK OFFICE